A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
What is the purpose of this trial?
The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab in combination with ipilimumab in treating patients/subjects with advanced renal cell carcinoma.
- Ages18 years and older
- Trial withBristol-Myers Squibb Research and Development
- Start Date08/27/2017
- End Date01/16/2022
- Last Updated07/02/2019
- Study HIC#2000020529